Introduction
The insulin-like growth factors or somatomedins are growth hormone-dependent polypeptides. They stimulate sulphate incorporation into cartilage, they have insulin-like activities and they stimulate growth of cultured cells (1, 2) .
Apart from the Isolation on the basis of different biological properties and the different purification procedures, recent studies document that somatomedin-C (SM-C), somatomedin-A (SM-A) and insulin-like growth factor I (IGF I) are chemically identical and indistinguishable in radioligand and biological assay Systems (3, 4) . SM-C/IGFI measurement has been used in screening for growth hormone deficiency and in contrast, high levels of SM-C/IGF I are found in acromegaly.
During recent years, radioimmunoassays for this analyte have been developed, and radioimmunoassays are now commercially available. The main problem in measuring this analyte is the presence of a serum binding protein for SM-C/IGF I. This serum binding protein is only partially saturated with IGF I (5) and consequently a radioimmunological determination of IGF I in whole serum leads to several difficulties. Therefore the conditions used for IGF I and SM-C radioimmunoassays were different. Some authors measured IGF I in whole serum under equilibrium (6) or non-equilibrium conditions (7) . Other groups have measured IGF I after Separation of IGF I from its binding protein(s) by gel filtration (8) or acidethanol extraction (9) . This report describes the development of a highly sensitive and specific radioimmunoassay for IGF I and its application to sera of normal subjects, patients with acromegaly and hypophysectomized patients. IGF I was measured in sera of these patients after Separation from its binding protein(s). The results obtained with this assay were compared with the results obtained after measurement of IGF I in the sera of the same patients with two commercially available radioimmunoassays for SM-C.
Purification of IGF I
IGF I was purifled s described previously (10) . Lyophilized human serum was extracted with. acid-ethanol. The extract was precipitated with acetone-ethariol, and the precipitate was chromatographed on a Sephadex G-50 column (K50/100, Pharmacia) in 0.1 mol/1 acetic acid. The IGF I-contaiiiing fractions from the Sephadex G-50 column wereffurther purifled by prep arative isoelectric focusing over a r nge between pH 3.0 and pH 9.0. The IGF I used to prepare the immunogen contained material which isofocused at a pl of 8.5 ± 0.2 and was free of immunoreactive insulin.
The IGF I used for radioimmunoassay was purified from the IGF I-containing fractions from Sephadex G-50 chromatography by FPLC-reversed phase chromatography, using a Pep RPC HR 5/5 column (Pharmacia, Uppsala). 
Production of antiserum
The antigen used for immunization was prepared by conjugating IGF I to bovine serum albumin using l-ethyl-3-(3-dimethylaminopropyl)-carbodiimide s* the coupling agent. Bovine serum albumin (3.8 mg) and IGF Ϊ preparation (3 mg) were dissolved in 0.9ml of .l mol/1 phosphate buffer, pH 7.4. To this solution, 0.1 ml of a l-ethyl-3-(3-dimethylaminopropyl)-carbodiimide solution (300 g/l phosphate buffer) was added dropwise with stirring at 20 °C over 24 hours. The reaction mixture was then dialysed against 0.15 mol/1 sodium chloride for 16 hours.
Three Chinchilla rabbits weighing approximately 4 kg were immunized. For the first and second injection, each rabbit received about 600 μg of the IGF I bovine serum albumin complex emulsified in complete Freund?s adjuvant. The subseqment injections were carried out at 3-week intervals with 100μg of the IGF I bovine serum albumin complex, emulsified in incomplete Freund** adjuvant. Ten millilitres of blood were drawn from an ear vein after 3 weeks and biweekly thereafter.
Materials and Methods
Pure IGF I and IGF II were kindly supplied by Dr. /. Zapf, University of Z rich, SM-C by Dr. A. J. D'Ercole, University of North Carolina, Chapel Hill. Human insulin was a gift from Eli Lilly and Company, Indianapolis. Epidermal growth factor and fibroblast growth factor were purchased from Serva, Heidelberg. Radioimmunoassays for SM-C were purchased from Nichols Institute Diagnostics, San Juan Capistrano, California 92675 (kit A) and from Immuno Nuclear Corporation, Stillwater, Minnesota 55082 (kit B). Goat anti-rabbit IgG was purchased from Miles Scientific, Bayer Diagnostics, Munich.
Extraction of serum
Twenty flve micr litres of each serum sample were acidified with 0.5ml of 0.5 mol/1 HC1. The Sep-Pak C18 cartridge (Waters Ass., Milford, M A 01757) was washed with methanol and subsequently equilibrated with 0.5 mol/1 acetic acid. The serum sample was applied to the cartridge and chromatographed in 0.5 mol/1 acetic acid with a flow rate of 0.5 ml/naSn. Finally IGF I was eluted with 5 ml of methanol. The methanol was evaporated and the dried samples were then dissolved in 25 μΐ of assay buffer and used at different dilutions in the radioimmunoassay.
* *
Radioimmunoassay of IGF I
The assay was carried out at 4°C in a phosphate/albumin buffer, pH 7.5, containing 200 mg/1 protamine sulphate, 4.14 g/l sodium phosphate, 2.5 g/l bovine serum albumin, 3.72 g/l EDTA and 0.2 g/i Na-azide. The final volume of the reaction mixture was 500 μΐ. Extracted serum sample (50 μΐ) was added to 100 μΐ of l : 10000 diluted IGF I antiserum. After 2 hours, 100 μΐ of 125 I-labaled IGF I (~ 30000 counts/min) was added and the mixture was incubated for another 20 hours at 4 °C, followed by the addition of 100 μΐ of 0.1 mol/1 EDTA solution and 200 μΐ of aqueous normal rabbit serum (volume fraction 0.02). After l hour, the second antibody (100 μΐ of goat antirabbit gamma globulin serum, diluted l : 4 with assay buffer) was added and the mixture was incubated for l hour at 4 °C. Then 500 μΐ of a 60 g/l polyethylene glycol (M r 6000-7500) solution was added. After 5 min the tubes were centrifuged (15 min, 3000 min" 1 at 4 °C). The supernatant was poured off and the precipitate was counted in a gamma counter (1290 Gamma-Trac, Tracor Analytic). Samples were assayed in triplicate at two or more concentrations.
Patients
Most blood saraples were obtained between 8 and 11 a. m. The 108 normal adult subjects ranged in age from 24 to 65 years. None was receiving medication at the time of sampling.
The 17 acromegalic patients had elevated basal immunoreactive growth hormone levels which did not fall below 6 μg/l after the oral administration of a 100 g glucose load. The six patients with hyperprolactinaemia had elevated immunoassayable serum prolactin levels (> 100 ug/1). The sera from 7 patients after hypophysectomy had decreased basal serum concentrations of immunoreactive growth hormone. The absence of growth hormone was demonstrated in four hypophysectomized patients.
Results
Characteristics of the antiserum to IGF I Antibodies to IGF I were detectable in the serum of two of the three immunized rabbits 6 weeks after the first injection of IGF I. Nine weeks after the first injection a f rther rise of the antibody titre was observed, which remained constant during the following immunization. The antiserum was used at a l : 10000 dilution for the radioimm rioassay. At this diluti n the antiserum bound 64% of the factor in the radioimm noassay. The cross reactivity of IGF I (Ulm), IGF I (Z rich) and somatomedin-C in the radioimm noassay was similar. No cross reactivity was observed with IGF II, human insulin, epidermal growth factor and fibroblast growth factor.
IGF I RIA in extracted serum
For our radioimm noassay IGFI was separated from its earrier protein(s) by Sep-Pak C18 cartridges. When serum was extracted using C18 cartridges the mean IGFI concentration was 379 ±159 μg/l in normal subjects, 3340 ± 1094 μg/l in acromegalic patients, and 52 + 11 μg/l in growth-hormone deficient patients ( fig. 2) . The serum IGF I concentration in six patients with hyperprolactinaemia was 433 ± Different dilutions of the extracted sera showed displacement curves parallel to the Standard curve. Table l shows the IGFI values in 10 sera after different extraction procedures. The different extraction procedures were compared by measuring a total of 53 samples.
After gel chromatography of the same samples in 0.1 mol/1 acetic acid, the mean IGFI level in normal subjects was lower (198 ± 48 μg/l). When serum was extracted with acid-ethanol according to the method described by Daughaday et al. (9) , the IGF I values were higher than those after gel chromatography. After extraction with C18 cartridges, the mean IGF I level was about 15% higher than after acid-ethanol extraction. Table 4 shows SM-C/IGFI values, measured by the different radioimmunoassays in sera of normal subjects, acromegalic patients, hypophysectomized patients and patients with hyperprolactinaemia.
The main difference in these assays was the fact that the SM-C/IGF I concentration was measured in whole t serum by kit A and in extracted serum by kit B and by the in-house method. The serum was extracted by Sep-Pak C18 cartridges in both radioimmunoassays. Furthermore, the SM-C/IGF I values were stated s μg/l in the in-house method and s U/l in kit A and s mol/1 in kit B.
The intra-assay variability, expressed s the coefficient of Variation was 3.97% in kit A and 6.86% in kit B. The interassay variability, determined by measuring the same samples in 6 assays, was 9.82% for kit A and 10.24% for kit B.
The sensitivity of the assays, s defined by that quantity of the Standard that reduced the maximal binding of Using kit A, which determined the SM-C levd in whole serum, the SM-C level in,normal subjects was between 400 U/l and 1800 U/l, in'acromegalic patients it was between 4000 U/l and 6200 U/l, in hypophysectomized patients it was between 190 U/l and 300 U/L The serum SM-C values in patients with hyperprolactinaemia were between 480 U/l and 1100 U/L Using kit B, the SM-C level in normal subjects was between 12. 
Discussion
This study preseiits a new radioimmunoassay for the measurement of IGF L
The antibody in this assay has a great affinity for IGF I and does not recognize IGF II, and is therefore very specific.
The main problem encountered in the measurement of IGF I in serum is the fact that IGF I is bound to carrier proteins. Probably less than l % of total IGFs circulate in a free form. Two size forms of carrier protein have been recognized in human serum. About 80% of the IGF is bound to the larger form which has a molecular weight of 150000. The rest of the IGF is bound to a smaller form with a molecular weight of about 40000 (11, 12) .
The binding of IGFs to carrier proteins is highly specific and of high affinity. Apparent association constants of 0.2-l nmol/1 have been described (13, 14, 15) which are comparable to the affinity of the binding of IGF I to most of its binding sites on the cell membrane.
Since the serum carrier protein is only partially saturated with IGF I (5), the radioimmunological determination of IGF I in whole serum is complicated. The labelled IGF I may compete with the unlabelled IGF I not only for its binding sites to the antibody but also for its binding to the carrier proteins. Therefore the concentration of IGF I carrier proteins may influence the results of the radioimmunoassay.
The values obtained for IGF I in whole serum with our inhouse assay were dependent on the serum dilution. A similar observation has been described by Daughaday et al. (9) and Zapfet al. (8) .
Therefore we decided to determine IGF I in extracted serum using Sep-Pak C18 cartridges for the Separation of IGF I from its carrier proteins. However, other methods for the Separation of IGF I from its carrier proteins have been described. We tested these different Separation procedures and found that after a Separation of IGF I from its carrier protein by gel chromatography the measured IGF I values were more than 40% lower than those determined after an acid-ethanol extraction. These differences are due to a great loss of IGFI.during gel chromatography. The total recovery of exogenous IGFI added to serum was 60 -65%. Zapf et al. reported a total recovery by gel chromatography of 74%, whereas Daughaday et al. described a total recovery of 100% by acid-ethanol extraction. After Separation of IGF I from its binding protein by SepPak C18 cartridges, our measured IGF I values werẽ 15% higher than those obtained after acid-ethanol extraction. This may be due to a loss of IGF I during our Separation procedure by acid-ethanol. The total recovery after acid-ethanol treatment was ~ 90%, whereas the total recovery by Sep-Pak C18 cartridges was about 100%. On the basis of the excellent recovery by the cartridge procedure we conclude that this method is superior to Sephadex chromatography.
The comparison of the in^house* radioimmünoassay with kit A and kit B shows that the values of kit B and the inJiouse method correlate with each other. The few discrepancies may be due to the antibody or the quality of the labelled or unlabelled IGF I itself.
The method used with kit A was described by Für-lanetto et al. (7), who developed a method for IGF I/ SM-C in whole serum, using a serum pool (l U/l of IGF I) äs Standard. Therefore, a direct comparison of the in-house assay with this method is difficült.
Since the values were given in U/l, oidy their relation* ship to each other may be examined.
Our present in^house assay shows a high specificity for IGF I and a high sensitivity. As little äs 0.1 g/l of IGF I can be detected. The üse of C18 cartridges for the Separation of IGF I from its binding protein makes it possible to process a small amount of serum (25 ) and a great nümber of serum samples (more than 100 per day). The assay is suitable for roütine use.
